These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 28941581)

  • 1. Use of frailty to predict survival in elderly patients with early stage non-small-cell lung cancer treated with stereotactic body radiation therapy.
    Franco I; Chen YH; Chipidza F; Agrawal V; Romano J; Baldini E; Chen A; Colson Y; Hou Y; Kozono D; Wee J; Mak R
    J Geriatr Oncol; 2018 Mar; 9(2):130-137. PubMed ID: 28941581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing Outcomes of Patients With Early-Stage Non-Small-Cell Lung Cancer Treated With Stereotactic Body Radiotherapy Based on Frailty Status.
    Raghavan G; Shaverdian N; Chan S; Chu FI; Lee P
    Clin Lung Cancer; 2018 Sep; 19(5):e759-e766. PubMed ID: 29954680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic body radiation therapy versus conventionally fractionated radiation therapy for early stage non-small cell lung cancer.
    Haque W; Verma V; Polamraju P; Farach A; Butler EB; Teh BS
    Radiother Oncol; 2018 Nov; 129(2):264-269. PubMed ID: 30031630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study.
    Watanabe K; Katsui K; Sugiyama S; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
    Radiat Oncol; 2021 Feb; 16(1):39. PubMed ID: 33622369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lung stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer in the very elderly (≥80years old): Extremely safe and effective.
    Kreinbrink P; Blumenfeld P; Tolekidis G; Sen N; Sher D; Marwaha G
    J Geriatr Oncol; 2017 Sep; 8(5):351-355. PubMed ID: 28739159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
    Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC).
    von Reibnitz D; Shaikh F; Wu AJ; Treharne GC; Dick-Godfrey R; Foster A; Woo KM; Shi W; Zhang Z; Din SU; Gelblum DY; Yorke ED; Rosenzweig KE; Rimner A
    Acta Oncol; 2018 Nov; 57(11):1567-1573. PubMed ID: 29873277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic index score predicts outcome of patients with Stage I non-small cell lung cancer after stereotactic body radiation therapy.
    Shi S; Ye L; Zhao Q; Hu Y; Huang Y; Chen G; Zeng Z; He J
    Jpn J Clin Oncol; 2019 Apr; 49(4):367-372. PubMed ID: 30715411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
    Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
    Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic body radiation therapy with higher biologically effective dose is associated with improved survival in stage II non-small cell lung cancer.
    Yan SX; Qureshi MM; Dyer M; Truong MT; Mak KS
    Lung Cancer; 2019 May; 131():147-153. PubMed ID: 31027693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elderly patients undergoing SBRT for inoperable early-stage NSCLC achieve similar outcomes to younger patients.
    Mancini BR; Park HS; Harder EM; Rutter CE; Corso CD; Decker RH; Husain ZA
    Lung Cancer; 2016 Jul; 97():22-7. PubMed ID: 27237023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Location Matters: Stage I Non-Small-cell Carcinomas of the Lower Lobes Treated With Stereotactic Body Radiation Therapy Are Associated With Poor Outcomes.
    Shaverdian N; Veruttipong D; Wang J; Kupelian P; Steinberg M; Lee P
    Clin Lung Cancer; 2017 Mar; 18(2):e137-e142. PubMed ID: 27908620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell lung cancer (NSCLC).
    Lucas JT; Kuremsky JG; Soike M; Hinson WW; Kearns WT; Hampton CJ; Blackstock AW; Urbanic J
    Lung Cancer; 2014 Jul; 85(1):59-65. PubMed ID: 24813936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response criteria in solid tumors (PERCIST/RECIST) and SUV
    Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
    Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. It's never too late: Smoking cessation after stereotactic body radiation therapy for non-small cell lung carcinoma improves overall survival.
    Roach MC; Rehman S; DeWees TA; Abraham CD; Bradley JD; Robinson CG
    Pract Radiat Oncol; 2016; 6(1):12-8. PubMed ID: 26598909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of pretreatment tumor growth rate on outcome of early-stage lung cancer treated with stereotactic body radiation therapy.
    Atallah S; Cho BC; Allibhai Z; Taremi M; Giuliani M; Le LW; Brade A; Sun A; Bezjak A; Hope AJ
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):532-8. PubMed ID: 24929163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prior Treatment for Non-small Cell Lung Cancer Is Associated With Improved Survival in Patients who Undergo Definitive Stereotactic Body Radiation Therapy for a Subsequent Lung Malignancy: A Retrospective Multivariate and Matched Pair Analysis.
    Farrugia MK; Jun Ma S; Hennon MW; Nwogu CE; Dexter EU; Picone AL; Demmy TL; Gomez-Suescun JA; Fung-Kee-Fung S; Yendamuri SS; Singh AK
    Am J Clin Oncol; 2021 Jan; 44(1):18-23. PubMed ID: 33264123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiotherapy for operable early-stage non-small cell lung cancer.
    Eriguchi T; Takeda A; Sanuki N; Tsurugai Y; Aoki Y; Oku Y; Hara Y; Akiba T; Shigematsu N
    Lung Cancer; 2017 Jul; 109():62-67. PubMed ID: 28577952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of histology in the outcomes of patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT) and adjuvant chemotherapy.
    Ernani V; Appiah AK; Baine MJ; Smith LM; Ganti AK
    Cancer Treat Res Commun; 2020; 24():100197. PubMed ID: 32777751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A propensity-matched analysis of surgery and stereotactic body radiotherapy for early stage non-small cell lung cancer in the elderly.
    Wang P; Zhang D; Guo XG; Li XM; Du LH; Sun BJ; Fang XQ; Guo YH; Guo J; An L; Qu GP; Liu CT
    Medicine (Baltimore); 2016 Dec; 95(52):e5723. PubMed ID: 28033277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.